Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher Cavanaugh is active.

Publication


Featured researches published by Christopher Cavanaugh.


The EMBO Journal | 2012

HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition

Wenyu Zhou; Michael Choi; Daciana Margineantu; Lilyana Margaretha; Jennifer Hesson; Christopher Cavanaugh; C. Anthony Blau; Marshall S. Horwitz; David M. Hockenbery; Carol B. Ware; Hannele Ruohola-Baker

The function of metabolic state in stemness is poorly understood. Mouse embryonicstem cells (ESC) and epiblast stem cells (EpiSC) are at distinct pluripotent statesrepresenting the inner cell mass (ICM) and epiblast embryos. Human embryonic stemcells (hESC) are similar to EpiSC stage. We now show a dramatic metabolic differencebetween these two stages. EpiSC/hESC are highly glycolytic, while ESC are bivalentin their energy production, dynamically switching from glycolysis to mitochondrialrespiration on demand. Despite having a more developed and expanding mitochondrialcontent, EpiSC/hESC have low mitochondrial respiratory capacity due to lowcytochrome c oxidase (COX) expression. Similarly, in vivo epiblastssuppress COX levels. These data reveal EpiSC/hESC functional similarity to theglycolytic phenotype in cancer (Warburg effect). We further show thathypoxia‐inducible factor 1α (HIF1α) is sufficient to drive ESC to aglycolytic Activin/Nodal‐dependent EpiSC‐like stage. This metabolic switch duringearly stem‐cell development may be deterministic.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Derivation of naïve human embryonic stem cells

Carol B. Ware; Angelique M. Nelson; Brigham Mecham; Jennifer Hesson; Wenyu Zhou; Erica C. Jonlin; Antonio J. Jimenez-Caliani; Xinxian Deng; Christopher Cavanaugh; Savannah Cook; Paul J. Tesar; Jeffrey Okada; Lilyana Margaretha; Henrik Sperber; Michael Choi; C. Anthony Blau; Piper M. Treuting; R. David Hawkins; Vincenzo Cirulli; Hannele Ruohola-Baker

Significance We report on generation of nontransgenic, naïve human pluripotent cells that represent the developmentally earliest state described for human established cells. Existing human ES cell lines in the later primed state can be toggled in reverse to naïve by exposure to histone deacetylase inhibitors prior to naïve culture. A new line was established directly from an eight-cell embryo under naïve culture conditions. We describe the naïve state in humans and show that naïve human ES cells have expanded endoderm developmental capacity. The naïve pluripotent state has been shown in mice to lead to broad and more robust developmental potential relative to primed mouse epiblast cells. The human naïve ES cell state has eluded derivation without the use of transgenes, and forced expression of OCT4, KLF4, and KLF2 allows maintenance of human cells in a naïve state [Hanna J, et al. (2010) Proc Natl Acad Sci USA 107(20):9222–9227]. We describe two routes to generate nontransgenic naïve human ES cells (hESCs). The first is by reverse toggling of preexisting primed hESC lines by preculture in the histone deacetylase inhibitors butyrate and suberoylanilide hydroxamic acid, followed by culture in MEK/ERK and GSK3 inhibitors (2i) with FGF2. The second route is by direct derivation from a human embryo in 2i with FGF2. We show that human naïve cells meet mouse criteria for the naïve state by growth characteristics, antibody labeling profile, gene expression, X-inactivation profile, mitochondrial morphology, microRNA profile and development in the context of teratomas. hESCs can exist in a naïve state without the need for transgenes. Direct derivation is an elusive, but attainable, process, leading to cells at the earliest stage of in vitro pluripotency described for humans. Reverse toggling of primed cells to naïve is efficient and reproducible.


Nature Methods | 2015

Fine-scale chromatin interaction maps reveal the cis-regulatory landscape of human lincRNA genes

Wenxiu Ma; Ferhat Ay; Choli Lee; Günhan Gülsoy; Xinxian Deng; Savannah Cook; Jennifer Hesson; Christopher Cavanaugh; Carol B. Ware; Anton Krumm; Jay Shendure; Carl Anthony Blau; Christine M. Disteche; William Stafford Noble; Zhijun Duan

High-throughput methods based on chromosome conformation capture have greatly advanced our understanding of the three-dimensional (3D) organization of genomes but are limited in resolution by their reliance on restriction enzymes. Here we describe a method called DNase Hi-C for comprehensively mapping global chromatin contacts. DNase Hi-C uses DNase I for chromatin fragmentation, leading to greatly improved efficiency and resolution over that of Hi-C. Coupling this method with DNA-capture technology provides a high-throughput approach for targeted mapping of fine-scale chromatin architecture. We applied targeted DNase Hi-C to characterize the 3D organization of 998 large intergenic noncoding RNA (lincRNA) promoters in two human cell lines. Our results revealed that expression of lincRNAs is tightly controlled by complex mechanisms involving both super-enhancers and the Polycomb repressive complex. Our results provide the first glimpse of the cell type–specific 3D organization of lincRNA genes.


Proceedings of the National Academy of Sciences of the United States of America | 2017

Cell population structure prior to bifurcation predicts efficiency of directed differentiation in human induced pluripotent cells

Rhishikesh Bargaje; Kalliopi Trachana; Martin N. Shelton; Christopher S. McGinnis; Joseph Xu Zhou; Cora Chadick; Savannah Cook; Christopher Cavanaugh; Sui Huang; Leroy Hood

Significance Induced pluripotent stem cells (iPSCs) open new possibilities for generating personalized disease models and drug testing. However, iPSC differentiation to a specific cell type can take weeks to complete, delaying the optimization process (maximize yield of desired cell types) for each patient’s iPSC. This task can be accelerated if the destination cell type can be determined early during cell lineage trajectory before cells manifest the desired phenotype. Our results indicate such a possibility: by quantifying the cell population structure during a critical state transition, we identified key regulators of lineages commitment and predicted the percentage of desired cell types for several protocol variations 2 wk in advance. Steering the differentiation of induced pluripotent stem cells (iPSCs) toward specific cell types is crucial for patient-specific disease modeling and drug testing. This effort requires the capacity to predict and control when and how multipotent progenitor cells commit to the desired cell fate. Cell fate commitment represents a critical state transition or “tipping point” at which complex systems undergo a sudden qualitative shift. To characterize such transitions during iPSC to cardiomyocyte differentiation, we analyzed the gene expression patterns of 96 developmental genes at single-cell resolution. We identified a bifurcation event early in the trajectory when a primitive streak-like cell population segregated into the mesodermal and endodermal lineages. Before this branching point, we could detect the signature of an imminent critical transition: increase in cell heterogeneity and coordination of gene expression. Correlation analysis of gene expression profiles at the tipping point indicates transcription factors that drive the state transition toward each alternative cell fate and their relationships with specific phenotypic readouts. The latter helps us to facilitate small molecule screening for differentiation efficiency. To this end, we set up an analysis of cell population structure at the tipping point after systematic variation of the protocol to bias the differentiation toward mesodermal or endodermal cell lineage. We were able to predict the proportion of cardiomyocytes many days before cells manifest the differentiated phenotype. The analysis of cell populations undergoing a critical state transition thus affords a tool to forecast cell fate outcomes and can be used to optimize differentiation protocols to obtain desired cell populations.


The Prostate | 2012

Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like

Eneida F. Vêncio; Angelique M. Nelson; Christopher Cavanaugh; Carol B. Ware; Daniel G. Milller; Julio C.O. Garcia; Ricardo Z. N. Vêncio; Michelle A. Loprieno; Alvin Y. Liu

CD90+ prostate cancer‐associated (CP) stromal cells represent a diseased cell type found only in tumor tissue. They differ from their normal counterpart in gene expression and inductive signaling. Genetic reprogramming by induced pluripotent stem (iPS) cell technology can effectively change adult cells into stem‐like cells through wholesale alteration of the gene expression program. This technology might be used to ‘erase’ the abnormal gene expression of diseased cells. The resultant iPS cells would no longer express the disease phenotype, and behave like stem cells.


Stem Cells | 2015

The GIPC1-Akt1 Pathway Is Required for the Specification of the Eye Field in Mouse Embryonic Stem Cells

Anna La Torre; Akina Hoshino; Christopher Cavanaugh; Carol B. Ware; Thomas A. Reh

During early patterning of the neural plate, a single region of the embryonic forebrain, the eye field, becomes competent for eye development. The hallmark of eye field specification is the expression of the eye field transcription factors (EFTFs). Experiments in fish, amphibians, birds, and mammals have demonstrated largely conserved roles for the EFTFs. Although some of the key signaling events that direct the synchronized expression of these factors to the eye field have been elucidated in fish and frogs, it has been more difficult to study these mechanisms in mammalian embryos. In this study, we have used two different methods for directed differentiation of mouse embryonic stem cells (mESCs) to generate eye field cells and retina in vitro to test for a role of the PDZ domain‐containing protein GIPC1 in the specification of the mammalian eye primordia. We find that the overexpression of a dominant‐negative form of GIPC1 (dnGIPC1), as well as the downregulation of endogenous GIPC1, is sufficient to inhibit the development of eye field cells from mESCs. GIPC1 interacts directly with IGFR and participates in Akt1 activation, and pharmacological inhibition of Akt1 phosphorylation mimics the dnGIPC1 phenotype. Our data, together with previous studies in Xenopus, support the hypothesis that the GIPC1‐PI3K‐Akt1 pathway plays a key role in eye field specification in vertebrates. Stem Cells 2015;33:2674–2685


Journal of Cellular Physiology | 2016

Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming

Gisely T. Borges; Eneida F. Vêncio; Sue Ing Quek; Adeline Chen; Diego M. Salvanha; Ricardo Z. N. Vêncio; Holly M. Nguyen; Robert L. Vessella; Christopher Cavanaugh; Carol B. Ware; Pamela Troisch; Alvin Y. Liu

The lineage relationship between prostate adenocarcinoma and small cell carcinoma was studied by using the LuCaP family of xenografts established from primary neoplasm to metastasis. Expression of four stem cell transcription factor (TF) genes, LIN28A, NANOG, POU5F1, SOX2, were analyzed in the LuCaP lines. These genes, when force expressed in differentiated cells, can reprogram the recipients into stem‐like induced pluripotent stem (iPS) cells. Most LuCaP lines expressed POU5F1, while LuCaP 145.1, representative of small cell carcinoma, expressed all four. Through transcriptome database query, many small cell carcinoma genes were also found in stem cells. To test the hypothesis that prostate cancer progression from “differentiated” adenocarcinoma to “undifferentiated” small cell carcinoma could involve re‐expression of stem cell genes, the four TF genes were transduced via lentiviral vectors into five adenocarcinoma LuCaP lines—70CR, 73CR, 86.2, 92, 105CR—as done in iPS cell reprogramming. The resultant cells from these five transductions displayed a morphology of small size and dark appearing unlike the parentals. Transcriptome analysis of LuCaP 70CR* (“*” to denote transfected progeny) revealed a unique gene expression close to that of LuCaP 145.1. In a prostate principal components analysis space based on cell‐type transcriptomes, the different LuCaP transcriptome datapoints were aligned to suggest a possible ordered sequence of expression changes from the differentiated luminal‐like adenocarcinoma cell types to the less differentiated, more stem‐like small cell carcinoma types, and LuCaP 70CR*. Prostate cancer progression can thus be molecularly characterized by loss of differentiation with re‐expression of stem cell genes. J. Cell. Physiol. 231: 2040–2047, 2016.


Methods | 2018

Using DNase Hi-C techniques to map global and local three-dimensional genome architecture at high resolution

Wenxiu Ma; Ferhat Ay; Choli Lee; Günhan Gülsoy; Xinxian Deng; Savannah Cook; Jennifer Hesson; Christopher Cavanaugh; Carol B. Ware; Anton Krumm; Jay Shendure; C. Anthony Blau; Christine M. Disteche; William Stafford Noble; Zhijun Duan

The folding and three-dimensional (3D) organization of chromatin in the nucleus critically impacts genome function. The past decade has witnessed rapid advances in genomic tools for delineating 3D genome architecture. Among them, chromosome conformation capture (3C)-based methods such as Hi-C are the most widely used techniques for mapping chromatin interactions. However, traditional Hi-C protocols rely on restriction enzymes (REs) to fragment chromatin and are therefore limited in resolution. We recently developed DNase Hi-C for mapping 3D genome organization, which uses DNase I for chromatin fragmentation. DNase Hi-C overcomes RE-related limitations associated with traditional Hi-C methods, leading to improved methodological resolution. Furthermore, combining this method with DNA capture technology provides a high-throughput approach (targeted DNase Hi-C) that allows for mapping fine-scale chromatin architecture at exceptionally high resolution. Hence, targeted DNase Hi-C will be valuable for delineating the physical landscapes of cis-regulatory networks that control gene expression and for characterizing phenotype-associated chromatin 3D signatures. Here, we provide a detailed description of method design and step-by-step working protocols for these two methods.


Cell Cycle | 2018

Inducible CRISPR genome editing platform in naive human embryonic stem cells reveals JARID2 function in self-renewal

Amy Ferreccio; Julie Mathieu; Damien Detraux; Somasundaram Logeshwaran; Christopher Cavanaugh; Bryce L. Sopher; Karin A. Fischer; Thomas Bello; Assis M. Hussein; Shiri Levy; Savannah Cook; Sonia Sidhu; Filippo Artoni; Nathan J. Palpant; Hans Reinecke; Yuliang Wang; Patrick J. Paddison; Charles E. Murry; Suman Jayadev; Carol B. Ware; Hannele Ruohola-Baker

ABSTRACT To easily edit the genome of naïve human embryonic stem cells (hESC), we introduced a dual cassette encoding an inducible Cas9 into the AAVS1 site of naïve hESC (iCas9). The iCas9 line retained karyotypic stability, expression of pluripotency markers, differentiation potential, and stability in 5iLA and EPS pluripotency conditions. The iCas9 line induced efficient homology–directed repair (HDR) and non-homologous end joining (NHEJ) based mutations through CRISPR-Cas9 system. We utilized the iCas9 line to study the epigenetic regulator, PRC2 in early human pluripotency. The PRC2 requirement distinguishes between early pluripotency stages, however, what regulates PRC2 activity in these stages is not understood. We show reduced H3K27me3 and pluripotency markers in JARID2 2iL-I-F hESC mutants, indicating JARID2 requirement in maintenance of hESC 2iL-I-F state. These data suggest that JARID2 regulates PRC2 in 2iL-I-F state and the lack of PRC2 function in 5iLA state may be due to lack of sufficient JARID2 protein.


The Journal of Urology | 2016

MP62-18 CONVERSION OF ADENOCARCINOMA TO SMALL CELL CARCINOMA-LIKE BY REPROGRAMMING

Gisely T. Borges; Eneida Franco Vêncio; Sue-Ing Quek; Adeline Chen; Diego M. Salvanha; Ricardo Z. N. Vêncio; Holly M. Nguyen; Robert L. Vessella; Christopher Cavanaugh; Carol B. Ware; Pamela Troisch; Alvin Y. Liu

Collaboration


Dive into the Christopher Cavanaugh's collaboration.

Top Co-Authors

Avatar

Carol B. Ware

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Savannah Cook

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Alvin Y. Liu

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xinxian Deng

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adeline Chen

University of Washington

View shared research outputs
Researchain Logo
Decentralizing Knowledge